Pathogenesis and potential antiviral therapy of complications of smallpox vaccination

Antiviral Research

Volumn 58, Issue 2, 2003, Pages 101-114

  Bray, Mike ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral therapy; Cidofovir; Eczema vaccinatum; Generalized vaccinia; Interferon; Orthopoxvirus; Progressive vaccinia; Ribavirin; Smallpox; Vaccination complications; Vaccinia keratitis; Vaccinia virus

Indexed keywords

2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; ANTIVIRUS AGENT; BETA INTERFERON; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CIDOFOVIR; IDOXURIDINE; IMIQUIMOD; INTERFERON; METISAZONE; NUCLEOSIDE DERIVATIVE; RESIQUIMOD; RIBAVIRIN; SMALLPOX VACCINE; STEROID; TRIFLURIDINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; VIDARABINE;

ATOPIC DERMATITIS; BACTERIAL SUPERINFECTION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; ECZEMA; ERYTHEMA MULTIFORME; FUNGAL MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; INFECTION; INJECTION SITE; NEPHROTOXICITY; NONHUMAN; OCULAR VACCINIA; POSTVACCINAL ENCEPHALITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN INJURY; SMALLPOX; STEROID THERAPY; VACCINATION; VACCINATION REACTION; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; ORTHOPOXVIRUS; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 0038059031     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00008-1     Document Type: Review

References (105)

1. Baker R., Bray M., Huggins J. Potential antiviral therapeutics for smallpox and other orthopoxvirus infections. Antiviral Res. 57:2003;13-23.
2. Bauer, D.J., 1965. Chemoprophylaxis of smallpox and treatment of vaccinia gangrenose with 1-methylisatin 3-thiosemicarbazone. Antimicrob. Agents Chemother. pp. 544-548.
3. Bienvenu B., Martinez F., Devergie A., Rybojad M., Rivet J., Bellenger P., Morel P., Gluckman E., Lebbe C. Topical use of cidofovir induced acute renal failure. Transplantation. 73:2002;661-662.
4. Blattner R.J., Normal J.O., Heys F.M., Aksu I. Antibody response to cutaneous inoculation with vaccinia virus: viremia and viruria in vaccinated children. J. Pediatr. 64:1964;839-852.
5. Brainerd H., Hanna L., Jawetz E. Methisazone in progressive vaccinia. New Engl. J. Med. 276:1967;620-624.
6. Bray, M., Wright, M.E., 2003. Progressive vaccinia. Clin. Infect. Dis. (in press).
7. Burke D., Brundage J., Herbold J., Berner W., Gardner L., Gunzenhauser J., Voskovitch J., Redfield R. Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. New Engl. J. Med. 317:1987;131-136.
8. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J. Eur. Acad. Dermatol. Venereol. 14:2000;484-488.
9. Centers for Disease Control and Prevention, 2003. Smallpox vaccination and adverse reactions: guidance for clinicians. Morbidity Mortality Weekly Rep. 52, 1-29.
10. Chan L., Robinson N., Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J. Invest. Dermatol. 117:2001;977-983.
11. Conybeare E.T. Illness attributed to smallpox vaccination during 1951-1960. Monthly Bull. Ministry Health Public Health Lab. Serv. 23:1964;126-133.
12. Copeman P.W.M., Wallace H.J. Eczema vaccinatum. Br. Med. J. 2:1964;906-908.
13. Czerny C., Eis-Hubinger A., Mayr A., Sneweis K., Pfeiff B. Animal poxviruses transmitted from cat to man: current event with lethal end. Zentralbl. Veterinarmed. 38:1991;421-431.
14. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:2001;382-397.
15. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55:2002;1-13.
16. De Clercq E., de Somer P. Effect of interferon, polyacrylic acid, and polymethacrylic acid on tail lesions in mice infected with vaccinia virus. Appl. Microbiol. 16:1968;1314-1319.
17. De Clercq E., Luczak M., Shugar D., Torrence P.F., Waters J.A., Witkop B. Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 151:1976;487-490.
18. Demkowicz W., Ennis F.A. Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans. J. Virol. 67:1993;1538-1544.
19. Douglas R., Lynch E., Spira M. Treatment of progressive vaccinia. Use of methisazone, vaccinia immune serum globulin and surgical debridement. Arch. Int. Med. 129:1972;980-983.
20. Driscoll, J., 2002. Antiviral Drugs. Ashgate Publishing, Ltd., Aldershot, UK.
21. Engler R., Kenner J., Leung D. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J. Allergy Clin. Immunol. 110:2002;357-365.
22. Ennis F.A., Cruz J., Demkowicz W.E., Rothman A.L., McClain D.J. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. J. Infect. Dis. 185:2002;1657-1659.
23. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I., 1988. Smallpox and Its Eradication. World Health Organization, Geneva.
24. Flexner C., Moss B., London W.T., Murphy B.R. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine. 8:1990;17-21.
25. Foley F., Greenawald K., Nash G., Pruitt B. Herpesvirus infection in burned patients. New Engl. J. Med. 282:1970;652-656.
26. Frey S., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., Atmar R.L., Edelman R., Nolan C.M., Belshe R.B. Clinical responses to undiluted and diluted smallpox vaccine. New Engl. J. Med. 17:2002a;1265-1274.
27. Frey S.E., Newman F.K., Cruz J., Shelton W.B., Tennant J.M., Polach T., Rothman A.L., Kennedy J.S., Wolff M., Belshe R.B., Ennis F.A. Dose-related effects of smallpox vaccine. New Engl. J. Med. 17:2002b;1275-1280.
28. Fulginiti V., Winograd L., Jackson M., Ellis P. Therapy of experimental vaccinal keratitis. Arch. Ophthalmol. 74:1965;539-544.
29. Fulginiti V., Kempe C., Hathaway W., Pearlman D., Sieber O.F., Eller J.J., Joyner J.J., Robinson A. Progressive vaccinia in immunologically deficient individuals. Birth Defects Original Articles Ser. 4:1968;129-145.
30. Geerinck K., Lukito G., Snoeck R., De Vos R., De Clercq E., Vanrenterghem Y., Degreef H., Maes B. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64:2001;543-549.
31. Gispen R., Lansberg H.P., Nanning W. The effect of antivaccinia gamma globulin on smallpox vaccination. Antonie Van Leeuwenhoek. 22:1956;89-102.
32. Glezerman M., Lunenfeld E., Cohen V., Sarov I., Movshovitiz M., Doerner T., Shoham J., Revel M. Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet. 1:1988;150-152.
33. Goldstein J., Neff J., Lane J., Koplan J. Smallpox vaccination reactions, prophylaxis and therapy of complications. Pediatrics. 55:1975;342-347.
34. Good R.A., Zak S.J., Condie R.M., Bridges R.A. Clinical investigation of patients with agammaglobulinemia and hypogammaglobulinemia. Pediatr. Clin. North Am. 7:1956;397-433.
35. Guillaume J.C., Saiag P., Wechsler J., Lescs M.C., Roujeau J.C. Vaccinia from recombinant virus expressing HIV genes. Lancet. 337:1991;1034-1035.
36. Gurvich E., Vilesova I. Vaccinia virus in postvaccinal encephalitis. Acta Virol. 27:1983;154-159.
37. Hanlon C.A., Niezgoda M., Shankar V., Niu H.S., Koprowski H., Rupprecht C.E. A recombinant vaccinia-rabies virus in the immunocompromised host: oral innocuity, progressive parenteral infection, and therapeutics. Vaccine. 15:1997;140-148.
38. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway. Nat. Immunol. 3:2002;196-200.
39. Henderson D.A. Bioterrorism as a public health threat. Emerg. Infect. Dis. 4:1998;488-492.
40. Henderson D.A., Inglesby T., Bartlett J., Ascher M.S., Eitzen E., Jahrling P.B., Hauer J., Layton M., McDade J., Osterholm M.T., O'Toole T., Parker G., Perl T., Russell P.K., Tonat K. Smallpox as a biological weapon: medical and public health management. J. Am. Med. Assoc. 281:1999;2127-2137.
41. Hugin A.W., Flexner C., Moss B. Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses. Cell. Immunol. 152:1993;499-509.
42. Hyndiuk R., Okumoto M., Damiano R., Valenton M., Smolin G. Treatment of vaccinial keratitis with vidarabine. Arch. Ophthalmol. 94:1976a;1363-1364.
43. Hyndiuk R., Seideman S., Leibsohn J.M. Treatment of vaccinial keratitis with trifluorothymidine. Arch. Ophthalmol. 94:1976b;1785-1786.
44. Jackson R.J., Ramsay A., Christensen C., Beaton S., Hall D., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75:2001;1205-1210.
45. Jaroszynska-Winberger B. Treatment with methisazone of complications following smallpox vaccination. Arch. Dis. Childhood. 45:1970;573-580.
46. Jones B., Galbraith J., Al-Hussaini M. Vaccinial keratitis treated with interferon. Lancet. I:1962;875-879.
47. Kaufman H. Treatment of viral diseases of the cornea and external eye. Prog. Retinal Eye Res. 19:1999;69-85.
48. Kaufman H., Nesburn A., Maloney E. Cure of vaccinia infection by 5-iodo-2-deoxyuridine. Virology. 18:1962;567-569.
49. Kempe C.H. Studies on smallpox and complications of smallpox vaccination. Pediatrics. 26:1960;176-189.
50. Kempe C.H., Berge T., England B. Hyperimmune vaccinal gamma globulin: source, evaluation and use in prophylaxis and therapy. Pediatrics. 18:1956;177-188.
51. Kemper A., Davis M., Freed G. Expected adverse events in a mass smallpox vaccination campaign. Effect. Clin. Pract. 5:2002;84-90.
52. Kern E.R. In vitro activity of potential anti-poxvirus agents. Antiviral Res. 57:2003;35-40.
53. Kern E.R., Hartline C., Harden E., Keith K., Rodriguez N., Beadle J.R., Hostetler K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:2002;991-995.
54. Kesson A., Ferguson J., Rawlinson W., Cunningham A. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin. Infect. Dis. 25:1997;911-914.
55. Kohonen-Corish M.R., King N.J., Woodhams C.E., Ramshaw I.A. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. J. Immunol. 20:1990;157-161.
56. Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968: national surveillance in the United States. New Engl. J. Med. 281:1969;1201-1208.
57. Lane J.M., Ruben F.L., Abrutyn E., Millar J.D. Deaths attributable to smallpox vaccination, 1959-1966 and 1968. J. Am. Med. Assoc. 212:1970a;441-444.
58. Lane J.M., Ruben F., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122:1970b;303-309.
59. Lane J.M., Millar J.D., Neff J.M. Smallpox and smallpox vaccination policy. Ann. Rev. Med. 22:1971;251-272.
60. Lee S.F., Buller R., Chansue E., Hanica W., Brunt E., Aquino T., Storch G., Pepose J. Vaccinia keratouveitis manifesting as a masquerade syndrome. Am. J. Ophthalmol. 117:1994;480-487.
61. Leung D. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J. Allergy Clin. Immunol. 105:2000;860-876.
62. Levy H., Lvovsky E. Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. J. Infect. Dis. 137:1978;78-81.
63. Lundstrom R. Complications of smallpox vaccination and their treatment with vaccinia immune gamma globulin. J. Pediatr. 49:1956;129-140.
64. MacKenzie N.G., Chapman O.W., Middleton P.J. Progressive vaccinia with chronic lymphatic leukaemia: a case report. N.Z. Med. J. 70:1969;324-327.
65. McClain D.J., Harrison S., Yeager C.L., Cruz J., Ennis F.A., Gibbs P., Wright M.S., Summers P.L., Arthur J.D., Graham J.A. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J. Infect. Dis. 175:1997;756-763.
66. McLean D. Methisazone therapy in pediatric vaccinia complications. Ann. N.Y. Acad. Sci. 284:1977;118-126.
67. Miller R., Tomai M., Harrison C., Bernstein D. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int. Immunopharmacol. 2:2002;443-451.
68. Mooney M., Janniger C., Schwartz R. Kaposi's varicelliform eruption. Cutis. 53:1994;243-245.
69. Naesens L., Snoeck R., Andrei G., Balzarini J., Neyts J., De Clercq E. HPMPC (cidofovir). PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8:1997;1-23.
70. Nakamura H., Aoki M., Tamai K., Oishi M., Ogihara T., Kaneda Y., Morishita R. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodoeoxynucleotides in NC/Nga atopic mouse model. Gene Ther. 9:2002;1221-1229.
71. Nanning W. Prophylactic effect of antivaccinia gamma-globulin against postvaccinal encephalitis. Bull. World Health Organ. 27:1962;317-324.
72. Neff J.M., Lane J.M., Pert J., Moore R., Millar J.D., Henderson D.A. Complications of smallpox vaccination. I. National survey in the United States, 1963. New Engl. J. Med. 276:1967a;125-132.
73. Neff J.M., Levine R.H., Lane J.M. Complications of smallpox vaccination, United States, 1963. II. Results obtained by four statewide surveys. Pediatrics. 39:1967b;916-923.
74. Neff J.M., Lane J.M., Fulginiti V.A., Henderson D.A. Contact vaccinia - transmission of vaccinia from smallpox vaccination. J. Am. Med. Assoc. 288:2002;1901-1905.
75. Neyts J., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:1993;242-246.
76. Neyts J., De Clercq E. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 45:2001;84-87.
77. Neyts J., Verbeken E., De Clercq E. Effect of 5-iodo-2′-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 46:2002;2842-2847.
78. Nimpfer T. On variola-vaccinia infection of burns in the course of hospital infection (German). Arch. Dermatol. Symph. 174:1936;518-524.
79. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., Gallo R.L., Leung D.Y. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. New Engl. J. Med. 347:2002;1151-1160.
80. Pavan-Langston, D., 1997. Ocular viral infections. In: Galasso, G.J., Whitley, R.J., Merigan, T.C. (Eds.), Antiviral Agents and Human Viral Diseases. Lippincott-Raven, Philadelphia, pp. 187-227.
81. Rao M., McFadzean J., Squires S. The laboratory and clinical assessment of an isothiazole thiosemicarbazone (M & B 7714) against pox viruses. Ann. N.Y. Acad. Sci. 130:1965;118-127.
82. Redfield R., Wright D., James W., Jones T., Brown C., Burke D. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. New Engl. J. Med. 316:1987;673-676.
83. Romanowski E., Bartels S., Gordon Y. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest. Ophthalmol. Vis. Sci. 40:1999;378-384.
84. Roos K.L., Eckerman N.L. The smallpox vaccine and postvaccinal encephalitis. Semin. Neurol. 22:2002;95-98.
85. Rudikoff D., Lebwohl M. Atopic dermatitis. Lancet. 351:1998;1715-1721.
86. Ruben F.L., Lane J.M. Ocular vaccinia. An epidemiologic analysis of 348 cases. Arch. Ophthalmol. 84:1970;45-48.
87. Scott G., Cartwright T., LeDu G., Dicker D. Effect of human fibroblast interferon on vaccination in volunteers. J. Biol. Stand. 6:1978;73-76.
88. Sepkowitz K. How contagious is vaccinia? New Engl. J. Med. 348:2003;439-452.
89. Sharma D.P., Ramsay A., Maguire D., Rolph R., Ramshaw I.A. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J. Virol. 70:1996;7103-7107.
90. Sharp J., Fletcher W. Experience of anti-vaccinia immunoglobulin in the United Kingdom. Lancet. I:1973;656-659.
91. Sidwell R., Allen L., Khare G., Huffman J., Witkowski J., Simon L., Robins R. Effect of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob. Agents Chemother. 3:1973;242-246.
92. Smee D., Bailey K., Wong M., Sidwell R. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52:2001;55-62.
93. Smee D., Bailey K., Sidwell R. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. Antiviral Res. 54:2002;113-120.
94. Snoeck R., Holy A., Dewolf-Peeters C., Van Den Oord J., De Clercq E., Andrei G. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 46:2002;3356-3361.
95. Stanley M. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27:2002;571-577.
96. Suarez V., Hankins G. Smallpox and pregnancy: from eradicated disease to bioterrorist threat. Obstet. Gynecol. 100:2002;87-93.
97. Sussman S., Grossman M. Complications of smallpox vaccination. Effects of vaccinia immune globulin therapy. J. Pediatr. 67:1965;1168-1173.
98. Suto H., Matsuda H., Mitsuishi K., Hira K., Uchida T., Unno T., Ogawa H., Ra C. NC/Nga mice: a mouse model for atopic dermatitis. Int. Arch. Allergy Immunol. 120(Suppl. 1):1999;70-75.
99. Turner W., Bauer D., Nimmo-Smith R. Eczema vaccinatum treated with N-methylisatin b-thiosemicarbazone. Br. Med. J. 1:1962;1317-1319.
100. Van Rooyen C.E., Casey J., Lee S.H.S., Faulkner R., Dincsoy H.P. Vaccinia gangrenosa and 1-methylisatin 3-thiosemicarbazone (methisazone). Can. Med. Assoc. J. 97:1967;160-165.
101. Wagner T., Horton V., Carlson G., Myhre P., Gibson S., Imbertson L., Tomai M. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine. 9:1997;837-845.
102. Wagner T., Ahonen C., Couture A., Gibson S., Miller R., Smith R., Reiter M., Vasilakos J., Tomai M. Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191:1999;10-19.
103. Wills V., Boorer C., Foster H., Hersey P., Kesson A. Vaccinia necrosum: a forgotten disease. Aust. N.Z. J. Surg. 70:2000;149-150.
104. Worthington M., Baron S. Effect of polyriboinosinic-polyribocytidylic acid and antibody on infection of immunosuppressed mice with vaccinia virus. J. Infect. Dis. 128:1973;308-311.
105. Worthington M., Conliffe M. Treatment of fatal disseminated vaccinia virus infection in immunosuppressed mice. J. Gen. Virol. 36:1977;329-333.